Journal of International Oncology››2021,Vol. 48››Issue (1): 1-10.doi:10.3760/cma.j.cn371439-20201208-00001
Received:2020-12-08Revised:2020-12-13Online:2021-01-08Published:2021-01-21
"
| 观测指标 | 评分 | ||
|---|---|---|---|
| 1 | 2 | 3 | |
| 肝性脑病(期别) | 0 | 1~2 | 3~4 |
| 腹腔积液 | 无 | 少量 | 中等量 |
| 白蛋白(g/L) | >35 | 28~35 | <28 |
| 凝血酶原时间延长(秒) | <4 | 4~6 | >6 |
| 总胆红素(μmol/L) | <34 | 34~50 | >50 |
"
| 分期 | T | N | M |
|---|---|---|---|
| ⅠA | T1a | N0 | M0 |
| ⅠB | T1b | N0 | M0 |
| Ⅱ | T2 | N0 | M0 |
| ⅢA | T3 | N0 | M0 |
| ⅢB | T4 | N0 | M0 |
| ⅣA | 任何T | N1 | M0 |
| ⅣB | 任何T | 任何N | M1 |
| [1] | Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338. pmid:26808342 |
| [2] | Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019,394(10204):1145-1158. DOI: 10.1016/S0140-6736(19)30427-1. doi:10.1016/S0140-6736(19)30427-1pmid:31248666 |
| [3] | 欧美同学会医师协会肝胆分会, 中国研究型医院学会分子诊断专委会, 中国临床肿瘤学会肝癌专委会, 等. 肝胆肿瘤分子诊断临床应用专家共识[J]. 中华肝胆外科杂志, 2020,26(2):81-89. DOI: 10.3760/cma.j.issn.1007-8118.2020.02.001. |
| [4] | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020,40(2):121-138. DOI: 10.19538/j.cjps.issn1005-2208.2020.02.01. |
| [5] | Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging—a systematic review and meta-analysis[J]. Radiology, 2015,275(1):97-109. DOI: 10.1148/radiol.14140690. pmid:25559230 |
| [6] | Liu X, Jiang H, Chen J, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis[J]. Liver Transpl, 2017,23(12):1505-1518. DOI: 10.1002/lt.24867. pmid:28886231 |
| [7] | Rao SX, Wang J, Wang J, et al. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: gadoxetic acid disodium[J]. J Dig Dis, 2019,20(2):54-61. DOI: 10.1111/1751-2980.12707. pmid:30693659 |
| [8] | Zeng MS, Ye HY, Guo L, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: a multicenter, open-label, phase Ⅲ study[J]. Hepatobiliary Pancreat Dis Int, 2013,12(6):607-616. DOI: 10.1016/s1499-3872(13)60096-x. doi:10.1016/s1499-3872(13)60096-xpmid:24322746 |
| [9] | Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase Ⅲ, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease[J]. Invest Radiol, 2010,45(3):133-141. DOI: 10.1097/RLI.0b013e3181caea5b. pmid:20098330 |
| [10] | Yoo SH, Choi JY, Jang JW, et al. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma[J]. Ann Surg Oncol, 2013,20(9):2893-2900. DOI: 10.1245/s10434-013-3001-y. pmid:23649931 |
| [11] | Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology, 2008,47(1):97-104. DOI: 10.1002/hep.21966. doi:10.1002/hep.21966pmid:18069697 |
| [12] | 中国临床肿瘤学会. 原发性肝癌诊疗指南[M]. 北京: 人民卫生出版社, 2020. |
| [13] | Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT[J]. J Hepatol, 2014,61(1):82-88. DOI: 10.1016/j.jhep.2014.03.012. doi:10.1016/j.jhep.2014.04.005 |
| [14] | Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group[J]. Ann Surg, 2013,257(5):929-937. DOI: 10.1097/SLA.0b013e31828329b8. doi:10.1097/SLA.0b013e31828329b8pmid:23426336 |
| [15] | Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma[J]. Semin Radiat Oncol, 2017,27(3):247-255. DOI: 10.1016/j.semradonc.2017.02.002. doi:10.1016/j.semradonc.2017.02.002pmid:28577832 |
| [16] | Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006,243(3):321-328. DOI: 10.1097/01.sla.0000201480.65519.b8. doi:10.1097/01.sla.0000201480.65519.b8pmid:16495695 |
| [17] | Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol, 2012,57(4):794-802. DOI: 10.1016/j.jhep.2012.05.007. doi:10.1016/j.jhep.2012.05.007pmid:22634125 |
| [18] | Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma[J]. Br J Surg, 2017,104(13):1775-1784. DOI: 10.1002/bjs.10677. doi:10.1002/bjs.10677pmid:29091283 |
| [19] | Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial[J]. J Clin Oncol, 2013,31(4):426-432. DOI: 10.1200/JCO.2012.42.9936. pmid:23269991 |
| [20] | Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]. Cancer, 2010,116(23):5452-5460. DOI: 10.1002/cncr.25314. doi:10.1002/cncr.25314pmid:20672352 |
| [21] | Chen QW, Ying HF, Gao S, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2016,40(3):309-314. DOI: 10.1016/j.clinre.2015.07.008. doi:10.1016/j.clinre.2015.07.008pmid:26428660 |
| [22] | Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390. DOI: 10.1056/NEJMoa0708857. doi:10.1056/NEJMoa0708857pmid:18650514 |
| [23] | Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of so-rafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009,10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. pmid:19095497 |
| [24] | Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. doi:10.1016/S0140-6736(18)30207-1pmid:29433850 |
| [25] | Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020,382(20):1894-1905. DOI: 10.1016/S0140-6736(18)30207-1. doi:10.1056/NEJMoa1915745pmid:32402160 |
| [26] | Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013,31(28):3501-3508. DOI: 10.1200/JCO.2012.44.5643. doi:10.1200/JCO.2012.44.5643pmid:23980077 |
| [27] | Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. doi:10.1016/S0140-6736(16)32453-9pmid:27932229 |
| [28] | El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. doi:10.1016/S0140-6736(17)31046-2pmid:28434648 |
| [29] | Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018,19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. doi:10.1016/S1470-2045(18)30351-6pmid:29875066 |
| [30] | Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with pre-viously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020,21(4):571-580. DOI: 10.1016/S1470-2045(20)30011-5. doi:10.1016/S1470-2045(20)30011-5pmid:32112738 |
| [31] | Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis[J]. Am J Roentgenol Radium Ther Nucl Med, 1965,93:200-208. pmid:14243011 |
| [32] | Durand-Labrunie J, Baumann AS, Ayav A, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2020,107(1):116-125. DOI: 10.1016/j.ijrobp.2019.12.004. doi:10.1016/j.ijrobp.2019.12.004pmid:32001057 |
| [33] | Takeda A, Sanuki N, Tsurugai Y, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation[J]. Cancer, 2016,122(13):2041-2049. DOI: 10.1002/cncr.30008. doi:10.1002/cncr.30008pmid:27062278 |
| [34] | Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of ste-reotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies[J]. Radiother Oncol, 2019,131:135-144. DOI: 10.1016/j.radonc.2018.12.005. doi:10.1016/j.radonc.2018.12.005pmid:30773180 |
| [35] | Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients[J]. Acta Oncol, 2014,53(3):399-404. DOI: 10.3109/0284186X.2013.820342. doi:10.3109/0284186X.2013.820342pmid:23962244 |
| [36] | Su TS, Liang P, Liang J, et al. Long-term survival analysis of ste-reotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2017,98(3):639-646. DOI: 10.1016/j.ijrobp.2017.02.095. doi:10.1016/j.ijrobp.2017.02.095pmid:28581406 |
| [37] | Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis[J]. Hepatology, 2019,69(6):2533-2545. DOI: 10.1002/hep.30591. doi:10.1002/hep.30591pmid:30805950 |
| [38] | Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma[J]. J Hepatol, 2020,73(1):121-129. DOI: 10.1016/j.jhep.2020.03.005. doi:10.1016/j.jhep.2020.03.005pmid:32165253 |
| [39] | Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma[J]. Liver Int, 2005,25(6):1189-1196. DOI: 10.1111/j.1478-3231.2005.01170.x. doi:10.1111/j.1478-3231.2005.01170.xpmid:16343071 |
| [40] | Kim KH, Kim MS, Chang JS, et al. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma[J]. Liver Int, 2014,34(5):784-794. DOI: 10.1111/liv.12436. doi:10.1111/liv.12436 |
| [41] | Koom WS, Seong J, Han KH, et al. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas?[J]. Int J Radiat Oncol Biol Phys, 2010,77(5):1433-1440. DOI: 10.1016/j.ijrobp.2009.07.1676. doi:10.1016/j.ijrobp.2009.07.1676pmid:19896779 |
| [42] | Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis[J]. JAMA Oncol, 2015,1(6):756-765. DOI: 10.1001/jamaoncol.2015.2189. doi:10.1001/jamaoncol.2015.2189pmid:26182200 |
| [43] | Chan SL, Chong CC, Chan AW, et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016[J]. World J Gastroenterol, 2016,22(32):7289-7300. DOI: 10.3748/wjg.v22.i32.7289. doi:10.3748/wjg.v22.i32.7289pmid:27621575 |
| [44] | Im JH, Yoon SM, Park HC, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area[J]. Liver Int, 2017,37(1):90-100. DOI: 10.1111/liv.13191. doi:10.1111/liv.13191pmid:27317941 |
| [45] | Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012,82(5):2004-2011. DOI: 10.1016/j.ijrobp.2011.03.019. doi:10.1016/j.ijrobp.2011.03.019pmid:21621346 |
| [46] | Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018,4(5):661-669. DOI: 10.1001/jamaoncol.2017.5847. doi:10.1001/jamaoncol.2017.5847pmid:29543938 |
| [47] | Kim YJ, Jung J, Joo JH, et al. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona Clinic Liver Cancer stage C[J]. Radiother Oncol, 2019,141:95-100. DOI: 10.1016/j.radonc.2019.08.009. doi:10.1016/j.radonc.2019.08.009pmid:31506181 |
| [48] | Lee IJ, Chung JW, Kim HC, et al. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors[J]. J Vasc Interv Radiol, 2009,20(1):22-29. DOI: 10.1016/j.jvir.2008.09.030. doi:10.1016/j.jvir.2008.09.030 |
| [49] | Rim CH, Kim CY, Yang DS, et al. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: a meta-analysis and systemic review[J]. Radiother Oncol, 2018,129(1):123-129. DOI: 10.1016/j.radonc.2018.02.030. doi:10.1016/j.radonc.2018.02.030pmid:29606524 |
| [50] | Katz AW, Chawla S, Qu Z, et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation[J]. Int J Radiat Oncol Biol Phys, 2012,83(3):895-900. DOI: 10.1016/j.ijrobp.2011.08.032. doi:10.1016/j.ijrobp.2011.08.032pmid:22172906 |
| [51] | O'Connor JK, Trotter J, Davis GL, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J]. Liver Transpl, 2012,18(8):949-954. DOI: 10.1002/lt.23439. doi:10.1002/lt.23439pmid:22467602 |
| [52] | Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J Hepatol, 2017,67(1):92-99. DOI: 10.1016/j.jhep.2017.02.022. doi:10.1016/j.jhep.2017.02.022pmid:28257902 |
| [53] | Chang CM, Wei CK, Lee CH, et al. Long-term follow-up of central hepatocellular carcinoma in comparison with non-central hepatocellular carcinoma[J]. Hepatogastroenterology, 2012,59(114):492-495. DOI: 10.5754/hge11361. doi:10.5754/hge11361pmid:21940385 |
| [54] | Wang WH, Wang Z, Wu JX, et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels[J]. Liver Int, 2015,35(12):2603-2610. DOI: 10.1111/liv.12857. doi:10.1111/liv.12857pmid:25939444 |
| [55] | Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019,37(24):2141-2151. DOI: 10.1200/JCO.18.02184. doi:10.1200/JCO.18.02184pmid:31283409 |
| [56] | Park YJ, Lim DH, Paik SW, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma[J]. J Gastroenterol, 2006,41(11):1099-1106. DOI: 10.1007/s00535-006-1895-x. doi:10.1007/s00535-006-1895-x |
| [57] | Zhou LY, Zeng ZC, Fan J, et al. Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors[J]. BMC Cancer, 2014,14:878. DOI: 10.1186/1471-2407-14-878. doi:10.1186/1471-2407-14-878pmid:25421498 |
| [58] | He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy[J]. Cancer, 2009,115(12):2710-2720. DOI: 10.1002/cncr.24300. doi:10.1002/cncr.24300pmid:19382203 |
| [59] | Jiang W, Zeng ZC, Zhang JY, et al. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma[J]. Clin Exp Metastasis, 2012,29(3):197-205. DOI: 10.1007/s10585-011-9442-4. doi:10.1007/s10585-011-9442-4pmid:22173728 |
| [60] | Park Y, Kim KS, Kim K, et al. Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study[J]. J Neurooncol, 2015,125(2):377-383. DOI: 10.1007/s11060-015-1926-7. doi:10.1007/s11060-015-1926-7pmid:26342711 |
| [61] | Wang MH, Ji Y, Zeng ZC, et al. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume[J]. Int J Radiat Oncol Biol Phys, 2010,76(2):467-476. DOI: 10.1016/j.ijrobp.2009.01.057. doi:10.1016/j.ijrobp.2009.01.057pmid:19406586 |
| [62] | Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma[J]. Radiother Oncol, 2014,111(3):412-417. DOI: 10.1016/j.radonc.2014.05.002. doi:10.1016/j.radonc.2014.05.002 |
| [63] | Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication[J]. Int J Radiat Oncol Biol Phys, 2010,78(4):1073-1080. DOI: 10.1016/j.ijrobp.2009.09.009. doi:10.1016/j.ijrobp.2009.09.009pmid:20207492 |
| [64] | Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010,76(3 Suppl):S94-S100. DOI: 10.1016/j.ijrobp.2009.06.092. doi:10.1016/j.ijrobp.2009.06.092pmid:20171524 |
| [65] | Koay EJ, Owen D, Das P. Radiation-induced liver disease and mo-dern radiotherapy[J]. Semin Radiat Oncol, 2018,28(4):321-331. DOI: 10.1016/j.semradonc.2018.06.007. doi:10.1016/j.semradonc.2018.06.007pmid:30309642 |
| [66] | Hu Y, Zhou YK, Chen YX, et al. 4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy[J]. Med Phys, 2016,43(7):4335. DOI: 10.1118/1.4953190. doi:10.1118/1.4953190pmid:27370148 |
| [67] | 中华学会放射肿瘤学分会. 2016年原发性肝癌放疗共识[J]. 中华放射肿瘤学杂志, 2016,25(11):1141-1150. DOI: 10.3760/cma.j.issn.1004-4221.2016.11.001. doi:10.3760/cma.j.issn.1004-4221.2016.11.001 |
| [68] | 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华临床感染病杂志, 2019,12(6):401-428. DOI: 10.3760/cma.j.issn.1674-2397.2019.06.001. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
